Today: 21 May 2026
Crypto stocks and Bitcoin ETFs wobble premarket after MSCI shelves crypto-treasury exclusion plan

Crypto stocks and Bitcoin ETFs wobble premarket after MSCI shelves crypto-treasury exclusion plan

New York, Jan 7, 2026, 07:33 (EST) — Premarket

  • MSCI said it will not move ahead with a plan to exclude “digital asset treasury” firms from its indexes, pending a broader review.
  • Bitcoin slipped about 2% in early trade, weighing on crypto-linked stocks and spot bitcoin ETFs.
  • Flows into U.S. spot bitcoin ETFs turned negative on Tuesday after a strong start to 2026, while ether ETFs stayed in the black.

MSCI said it will not proceed with a proposal to exclude digital asset treasury companies — firms whose digital asset holdings make up 50% or more of total assets — from its indexes, opting instead for a broader consultation on how non-operating companies should be treated. 

That matters because index rules are not academic. Passive funds and benchmark trackers buy and sell when lists change, and the trade can spill into other crypto proxies fast.

The timing is awkward, too. The first-week bounce in crypto has cooled, and the mood has shifted from “flows are back” to “flows are fickle,” with equities reacting to every policy nudge.

Digital asset treasury companies, often called DATCOs, surged in popularity in 2025 as more firms held tokens such as bitcoin and ether as their main treasury assets. Clear Street analyst Owen Lau said the MSCI decision “removes a material near-term technical risk,” while JonesTrading strategist Mike O’Rourke added he suspects any exclusion has been “postponed until later in the year.” Strategy, formerly MicroStrategy, reported this week a $17.44 billion fourth-quarter unrealized loss on digital assets tied to a decline in the value of its crypto stockpile. Reuters+1

Bitcoin fell 1.9% to about $91,974 and ether slipped 0.7% to $3,214, dragging the usual equity proxies with it. Strategy was down 4.1% in premarket trade, Coinbase fell 1.7%, and miners Marathon Digital and CleanSpark slid 2.6% and 2.4%; Riot Platforms bucked the tape, up about 1.3%. Among the biggest spot bitcoin ETFs, BlackRock’s iShares Bitcoin Trust (IBIT) and Fidelity’s FBTC were down around 2%.

ETF flow data is still doing some of the steering. Farside Investors data showed U.S. spot bitcoin ETFs — funds that hold bitcoin directly, rather than futures — flipped to a net outflow of $243.2 million on Tuesday after a $697.2 million inflow on Monday. IBIT took in $228.7 million on Tuesday, but Fidelity’s FBTC saw $312.2 million leave; U.S. ether ETFs drew $114.7 million of net inflows the same day. 

New competition is lining up in crypto funds as well. Morgan Stanley filed with the U.S. Securities and Exchange Commission on Tuesday for ETFs tied to the prices of bitcoin and solana, the first such move by a big U.S. bank; Morningstar ETF analyst Bryan Armour said a bank’s entry “adds legitimacy” and “others could follow.” Reuters

But MSCI’s pause is not a clean all-clear. If the index debate swings back toward treating crypto-heavy firms like quasi-funds, or bitcoin’s slide deepens, the same names that act like easy exposure can turn into forced de-risking.

Traders now turn to U.S. labor data, with ADP private payrolls due at 8:15 a.m. ET, the JOLTS openings report after the market opens, and Friday’s nonfarm payrolls on Jan. 9 — prints that can move rate-cut bets and, by extension, the appetite for high-beta trades like crypto stocks and ETFs.

Stock Market Today

  • Bitmine Immersion Technologies Uplists to NYSE, Holds 5M+ ETH as Ethereum Proxy, Launches MAVAN Staking
    May 21, 2026, 12:11 AM EDT. Bitmine Immersion Technologies (NYSE:BMNR) has become a major Ethereum proxy by accumulating over 5 million ETH, representing more than 4.3% of Ethereum's total supply. The company uplisted to the NYSE and introduced MAVAN, an institutional-grade Ethereum staking platform, shifting its focus beyond mining to include staking services. BMNR stock closed at $19.39, trading below analyst targets and experiencing recent price declines despite longer-term gains. Investors should watch Ethereum price trends, staking yields, and institutional adoption of MAVAN, while noting BMNR remains loss-making and has diluted shareholders.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Cipla share price slides after USFDA flags Pharmathen: what the Form 483 says
Previous Story

Cipla share price slides after USFDA flags Pharmathen: what the Form 483 says

UnitedHealth stock falls despite new price targets as Wall Street eyes Jan. 27 earnings
Next Story

UnitedHealth stock falls despite new price targets as Wall Street eyes Jan. 27 earnings

Go toTop